← Leaderboards
Alan Sandler
Indiana Univ-Purdue Univ At Indianapolis
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Mitchell Goldman$10,867,864
- Mark R. Kelley$16,203,613
- Kenneth H. Fife$1,137,888
- Md Michael Frank$0
- Jian-Ting Zhang$8,618,248
Others in their field
Top investigators on “Pharmacokinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$237,100,725
- Constance Ann Benson · University Of California, San Diego$151,891,628
- Richard L Schilsky · University Of Chicago$114,474,127
- Ronald T Mitsuyasu · University Of California Los Angeles$105,970,100
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,574,471
- Myron S Cohen · Family Health International$91,263,426
Research focus
PharmacokineticsClinical ResearchNeoplasm /Cancer ChemotherapyIntravenous AdministrationHuman SubjectHuman Therapy EvaluationClinical Trial Phase IDrug Screening /EvaluationCombination ChemotherapyCytotoxicityDosageDoxorubicinDrug Adverse EffectMultidrug ResistanceP GlycoproteinClearance RateAntineoplasticsEnzyme InhibitorsKidney Function
Grant awards (14)
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2002 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2002 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2001 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2001 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2000 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2000 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2000 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2000 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2000 · RR
LY231514 INTRAVENOUS EVERY 3 WEEKS IN ADVANCED CANCER$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION STUDY OF LY335979 ADMINISTERED INTRAVENOUSLY$0
M01 · FY2000 · RR